The BBSRC, one of the UK's largest UK bioscience funders, has announced Bristol will retain its Strategic Partnership (SP) status. The decision was announced this month following BBSRC's SP member triannual review. Bristol is one of only ten top-funded university partners with this status - which it has retained since 2012 recognising the University's long-term record for excellence in biosciences research.
Notably, Bristol is ranked fourth in average value of BBSRC-funded research grants portfolio between 1st April for 2019 – 2021 (triannual review period) equating to around £45 million.
Pro Vice-Chancellor for Research and Enterprise, Professor Phil Taylor, said: "It is gratifying to see this outcome and is testament to our exceptional bioscience research talent and world-class facilities for genomics, imaging, and biological chemistry. Our sustained investments in these areas, with significant and ongoing BBSRC support, has driven our internationally renowned strength in frontier bioscience, which we are immeasurably proud of. This underpinning research strength accelerates our innovation as we aim to contribute to addressing the major challenges facing society including climate change, brain function, infectious disease, and an ageing population.
"Our regional BBSRC-funded DTP (SWBio DTP3), now entering its 10th year, provides outstanding doctoral training to sustain future UK leadership in priority areas for bioscience alongside our BBSRC-funded longer-term programmes in synthetic biology, wheat genomics, and cell biology."
More on the Strategic Partnership can be found on the BBSRC website.
